Neuroscience CE Activities

Neuroscience blog

View Details

Improving the Management of Chronic Neurodegenerative Diseases with Interprofessional Collaboration & Care

Multiple sclerosis (MS) and Parkinson’s disease (PD) are 2 highly prevalent chronic progressive neurodegenerative disorders. Over time, the accumulation and subsequent worsening of the symptoms associated with these diseases can result in disability, impaired quality of life, loss of independence, and an increased burden on caregivers.  
View Details

New Treatments for SMA: Should We Offer Them to Adults?

Spinal muscular atrophy (SMA) is a genetic disorder and a devastating diagnosis for children and their families that can lead to death or a lifetime of severe disability and progressively limited mobility.

RMEI DECISION SUPPORT AIDS

View Details

The Evolving Role of Orexin-Based Therapy in Narcolepsy Type 1 Management

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.
View Details

Clearing the Path for the Accurate Diagnosis and Optimal Treatment of Bipolar Depression: A Clinical Convergence®

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.

LATEST NEUROSCIENCE ARTICLES

RSS Latest Neuroscience Articles
  • Progress in the Development of N-of-1 Therapy May 15, 2025
    Musunuru and colleagues1 describe in the Journal an innovative approach in which gene editing is applied in the treatment of a very rare disease, the severe urea-cycle disorder carbamoyl-phosphate synthetase 1 (CPS1) deficiency, which is usually fatal in early infancy in approximately half the infants who...
    Peter Marks
  • Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1 May 15, 2025
    In this phase 2 randomized, placebo-controlled trial involving 112 participants with narcolepsy type 1, oveporexton significantly improved measures of wakefulness, sleepiness, and cataplexy over a period of 8 weeks.
    Yves Dauvilliers, Giuseppe Plazzi, Emmanuel Mignot, Gert Jan Lammers, Rafael del Río Villegas, Ramin Khatami, Mitsutaka Taniguchi, Anson Abraham, Yaming Hang, Harisha Kadali, Marta Lamberton, Sarah Sheikh, Ellie Stukalin, Rachel Neuwirth, Todd J. Swick, Shinichiro Tanaka, Christian von Hehn, Philipp von Rosenstiel, Hao Wang, Alice Cai, Melissa Naylor, Tina Olsson
  • Science behind the Study: Targeting Orexin Receptors to Treat Narcolepsy May 15, 2025
    The author describes the scientific foundations of a trial of an orexin agonist to treat narcolepsy.
    Clifford B. Saper

RMEI LIGHTNING TALKS

View Details

4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we've learned so far

RMEI has released pairings of live and online programs approximately twice per year since 2016 grouped into “phases” which share clinical areas of focus and are based on findings from the previous phase of education. In total, 16 activities have launched to date with 4 activities currently live. The purpose of this analysis is to better understand the impact of multi-year iterative education on a clinical audience. Presented at: Society for Academic CME (SACME), virtual, February 2021; Accreditation Council for Continuing Medical Education (ACCME), virtual, April 2021.
View Details

Effectiveness of 5-year IBD Provider Online Educational Intervention Program

There is considerable practice variability among providers caring for inflammatory bowel disease (IBD) patients. Limited data exists on the effectiveness of educational interventions targeting IBD providers to address these gaps. We report outcomes for a 5-year provider education training program which culminated in an enduring online education resource and clinical decision support tool.